# Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

> **NCT04668209** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 31 (actual)

## Conditions studied

- Coronavirus

## Interventions

- **DRUG:** Silmitasertib

## Key facts

- **NCT ID:** NCT04668209
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-21
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-10-19
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** After 15 months of active enrollment and a lack of qualifying hospitalized COVID-19 patients, the Sponsor-Investigator, Marilyn Csete Glassberg, MD, decided to terminate recruitment before meeting the stated enrollment objectives.
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668209, "Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04668209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*